New drug cocktail aims to boost myeloma treatment before and after transplant
NCT ID NCT04802356
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called belantamab mafodotin (Blenrep) combined with standard therapy (VRd) in 50 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and helps control the disease before and after transplant. Participants receive the drugs in cycles, then a transplant, then more treatment to keep the cancer in check.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (Blenrep) combined with bortezomib, lenalidomide, and dexamethasone (VRd)
What this could lead to
If successful, this combination could improve response rates and extend disease control for newly diagnosed multiple myeloma patients undergoing transplant.
What could go wrong
This is an early-phase (Phase 2) trial with only 50 participants, so results may not apply to all patients. The drug combination carries risks like eye problems and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Universitario Hospitalario de Santiago
Santiago de Compostela, Galicia, 15706, Spain
-
Hospital General Universitario Morales Meseguer
Murcia, 30008, Spain
-
Hospital Gregorio Marañon
Madrid, Madrid, 28007, Spain
-
Hospital Infanta Leonor
Madrid, Spain
-
Hospital Son Llatzer
Palma de Mallorca, Balearic Islands, 07198, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Spain
-
Hospital Universitario de Salamanca
Salamanca, Castille and León, 37007, Spain
-
Hospital Universitario y Policlínico de la Fe
Valencia, Valencia, 46026, Spain
-
Hospital Virgen de la Arrixaca
Murcia, Spain
-
Hospital de Cabueñes
Gijón, Principality of Asturias, 33394, Spain